Tag: Biologics
GenSight Biologics: presentation of data on LUMEVOQ
(CercleFinance.com) – GenSight Biologics announces today that the efficacy and safety data of patients with Leber Hereditary Optic Neuropathy and carriers of the ND4 mutation treated with lenadogene nolparvovec (LUMEVOQÒ,…
GenSight Biologics: positive 3-year data for Lumevoq
(CercleFinance.com) – GenSight Biologics today announces efficacy and safety results at 3 years post-injection of Lumevoq in the REFLECT phase III clinical trial. The results show the maintenance of the…
GenSight Biologics: will present data on Lumevoq – 03/10/2023 at 10:15 am
(CercleFinance.com) – GenSight Biologics announces today that the Company will participate and present data on LUMEVOQ at medical conferences in the coming weeks. On Tuesday, March 14, Dr. Catherine Vignal,…
GenSight Biologics: will present data on Lumevoq
(CercleFinance.com) – GenSight Biologics announces today that the Company will participate and present data on LUMEVOQ at medical conferences in the coming weeks. On Tuesday, March 14, Dr. Catherine Vignal,…
GenSight Biologics announces the drawing of the first tranche of its credit agreement with the EIB – 02/06/2023 at 18:29
(AOF) – GenSight Biologics announces the drawdown of 8 million euros under the first tranche of its credit agreement with the European Investment Bank. The biopharmaceutical company specializing in gene…
GenSight Biologics obtains 12 ME of financing through a convertible bond issue
(Boursier.com) — GenSight Biologicsa biopharmaceutical company dedicated to the development and commercialization of innovative gene therapies for neurodegenerative diseases of the retina and central nervous system, announced today that it…
Gene therapy: GenSight Biologics raises 12 million euros from an American fund – 12/23/2022 at 10:17
(AOF) – GenSight Biologics, a biopharmaceutical company dedicated to the development and commercialization of gene therapies for neurodegenerative diseases of the retina and central nervous system, announces that it has…
Gensight biologics: ‘Low-dilutive’ financing being finalized
Read also (CercleFinance.com) – GenSight Biologics reported on Friday evening a cash position of 13.9 million as of September 30, compared to 24.1 million euros as of June 30. In…
GenSight Biologics: produced pilot batch of LUMEVOQ – 09/19/2022 at 10:54 am
(CercleFinance.com) – GenSight Biologics announces the successful production of the first pilot batch incorporating improvements in the manufacturing process of LUMEVOQ, the gene therapy for Leber’s hereditary optic neuropathy (LHON)…
GenSight Biologics: produces the first pilot batch of LUMEVOQ – 09/19/2022 at 11:05 am
(CercleFinance.com) – GenSight Biologics announces the successful production of the first pilot batch incorporating improvements in the manufacturing process of LUMEVOQ, the gene therapy for Leber’s hereditary optic neuropathy (LHON)…
Gensight biologics: Recruiting for the launch of Lumevoq
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
GenSight Biologics: recruiting for the launch of Lumevoq
(CercleFinance.com) – GenSight Biologics strengthens its management team to support the launch of Lumevoq in Europe. Philippe Motté is appointed Senior Vice-President, Regulatory Affairs and Quality, reporting to Bernard Gilly,…